Pipeline to Practice in Platinum-Resistant Ovarian Cancer: What's New, What's Next, and How to Prepare

Program Description

Ovarian cancer poses a profound clinical and quality-of-life burden, with most patients diagnosed at advanced stages. Those with platinum-resistant recurrence often experience repeated cycles of chemotherapy that exacerbate fatigue, pain, neurotoxicity, emotional distress, and functional limitations. For those progressing to platinum-resistant ovarian cancer (PROC), historical single-agent options offer modest response rates and limited progression-free survival, and are often associated with cumulative toxicities. Biomarker testing has emerged as a cornerstone of PROC management, enabling precision selection of therapies while minimizing potentially ineffective exposures and accelerating access to optimal care. This program will review how PROC and low-grade serous ovarian cancer management has shifted toward biomarker-driven precision therapies, with a focus on FRα overexpression, KRAS mutations, dMMR/MSI-H or TMB-H status, HER2 amplification, and other rare alterations. Pivotal trial data, pipeline therapies, and practical approaches for evaluating emerging evidence and dosing strategies will also be discussed. The program will also emphasize best practices to mitigate unique toxicities through proactive monitoring, patient education, EMR tools, and institutional protocols. By enhancing oncology pharmacists' expertise in biomarker assessment, real-world implementation, and safety optimization, this activity empowers them to guide precision treatment selection, streamline care pathways, and improve outcomes for patients with PROC.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: May 12, 2026
Expiration date: May 12, 2027
Learner level: Intermediate, Advanced
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply current guideline recommendations and clinical trial data to support treatment decisions and formulary planning for patients with platinum-resistant ovarian cancer (PROC), focusing on those with actionable biomarkers
• Compare emerging investigational therapies for platinum-resistant ovarian cancer, including their mechanisms of action, patient selection criteria, and clinical trial data
• Identify evidence-based strategies for monitoring, managing, and mitigating adverse effects of novel agents in oncology practice

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1CEU) under the ACPE universal activity number 0290-0000-26-118-H05-P The activity is available for CE credit through May 12, 2027

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Cassidy Blais, PharmD , has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Pfizer Inc, Daiichi sankyo

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Macara Desai; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com

Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms